Toma MI - Search Results

1

Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.

Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB. Toma MI, et al. Neoplasia. 2008 Jul;10(7):634-42. doi: 10.1593/neo.08160. Neoplasia. 2008. PMID: 18592004 Free PMC article.

2

Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma.

Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Füssel S, Wirth MP, Baretton GB. Toma MI, et al. Cancer Invest. 2011 Feb;29(2):123-9. doi: 10.3109/07357907.2010.535059. Epub 2011 Jan 6. Cancer Invest. 2011. PMID: 21210727

3

PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.

Toma MI, Wuttig D, Kaiser S, Herr A, Weber T, Zastrow S, Koch R, Meinhardt M, Baretton GB, Wirth MP, Fuessel S. Toma MI, et al. Genes Chromosomes Cancer. 2013 Mar;52(3):265-73. doi: 10.1002/gcc.22026. Epub 2012 Nov 2. Genes Chromosomes Cancer. 2013. PMID: 23125027

4

Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient.

Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, Hoefling C, Toma M, Grimm MO, Meye A, Rolle A, Wirth MP. Wuttig D, et al. Int J Cancer. 2009 Jul 15;125(2):474-82. doi: 10.1002/ijc.24353. Int J Cancer. 2009. PMID: 19391132

5

Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer.

Toma MI, Friedrich K, Meyer W, Fröhner M, Schneider S, Wirth M, Baretton GB. Toma MI, et al. Anal Quant Cytol Histol. 2010 Feb;32(1):1-10. Anal Quant Cytol Histol. 2010. PMID: 20701082

6

CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.

Wuttig D, Zastrow S, Füssel S, Toma MI, Meinhardt M, Kalman K, Junker K, Sanjmyatav J, Boll K, Hackermüller J, Rolle A, Grimm MO, Wirth MP. Wuttig D, et al. Among authors: toma mi. Int J Cancer. 2012 Sep 1;131(5):E693-704. doi: 10.1002/ijc.27419. Epub 2012 Feb 28. Int J Cancer. 2012. PMID: 22213152

7

Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.

Toma MI, Erdmann K, Diezel M, Meinhardt M, Zastrow S, Fuessel S, Wirth MP, Baretton GB. Toma MI, et al. PLoS One. 2014 Jul 15;9(7):e102262. doi: 10.1371/journal.pone.0102262. eCollection 2014. PLoS One. 2014. PMID: 25025847 Free PMC article.

8

Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.

Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, Kraemer K, Fuessel S, Toma M, Schwenzer B, Meye A, Grimm MO, Hakenberg OW, Jocham D, Wirth MP. Kunze D, et al. Int J Oncol. 2008 May;32(5):1049-56. Int J Oncol. 2008. PMID: 18425331

9

Growth of a Level III Vena Cava Tumor Thrombus Within 1 Month.

Froehner M, Heberling U, Zastrow S, Toma M, Wirth MP. Froehner M, et al. Urology. 2016 Apr;90:e1-2. doi: 10.1016/j.urology.2015.12.043. Epub 2016 Jan 6. Urology. 2016. PMID: 26772645

10

Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition?

Wuttig D, Kunze D, Fuessel S, Toma M, Stade J, Kotzsch M, Kappler M, Taubert H, Schwenzer B, Baretton G, Hakenberg OW, Meye A, Wirth MP. Wuttig D, et al. Int J Oncol. 2007 Jun;30(6):1317-24. doi: 10.3892/ijo.30.6.1317. Int J Oncol. 2007. PMID: 17487351

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters